7. First Come, First Served?The graph shows the downward-sloping demand for, and the upward-sloping supply of, flu jabs facing a clinic in a remote village. This clinic is the only place providing flu jabs to the residents of this village The equilibrium price is €per flu jab, and the equilibrium quantity isjabs per day.If the government imposes a maximum price of €14 per flu jab, there will beofjabs per day.At the price control of €14 per jab, the quantity supplied isper day. At this quantity, the maximum price the residents of this village arewilling to pay is €per jab.People will wait in line until the total cost of the flu jab (price for the jab plus waiting time) equals the maximum price they are willing to pay at thequantity supplied under the price control. On the graph, use the orange rectangle (square symbols) to shade the area representing the total value oftime wasted in line. The total value of time wasted in line is € 4036SupplyWasted Time Value32282420Controlled PriceDemand102030405060708090100QUANTITY (Jabs per day)The equilibrium price is €per flu jab, and the equilibrium quantity isjabs per day.If the government imposes a maximum price of €14 per flu jab, there will beof [jabs per day.At the price control of €14 per jab, the quantity supplied isper day. At this quantity, the maximum price the residents of this village arewilling to pay is €per jab.PRICE OF FLU JAB (Euros)

The equilibrium price is € per flu jab, and the equilibrium quantity is jabs per day. If the government imposes a maximum price of €14 per flu jab, there will be of jabs per day. At the price control of €14 per jab, the quantity supplied is per day. At this quantity, the maximum price the residents of this village are willing to pay is € per jab.

The equilibrium price is € per flu jab, and the equilibrium quantity is jabs per day. If the government imposes a maximum price of €14 per flu jab, there will be of jabs per day. At the price control of €14 per jab, the quantity supplied is per day. At this quantity, the maximum price the residents of this village are willing to pay is € per jab.

ENGR.ECONOMIC ANALYSIS

14th Edition

ISBN:9780190931919

Author:NEWNAN

Publisher:NEWNAN

Chapter1: Making Economics Decisions

Section: Chapter Questions

Problem 1QTC

See similar textbooks

Similar questions

Can you explain As members of the Baby Boom generation approach advanced ages, their demand for medical care will change. Referring to the graphs below, will this demand change be reflected in the movement from point A to to point B, or in the movement from D1 to D2? Please explain your answer.
How is the moral hazard problem relevant to the health care market?
1. If you are trying to use a RDD setup to evaluate the effect of health insurance on health, and you qualify for a health insurance subsidy if your family income is below $20,000. What's the running variable? What's treatment, and what's the outcome?
1. Fun with cost-sharing. An important distinction in health insurance is between the list price (PL) and out-of-pocket price (PP) of a medical good or service. The list price is the official price that the provider charges the insurance company, while the out-of-pocket price is the price that the insurance customer faces. Sometimes, the out-of-pocket price depends on the list price. a. Suppose a consumer’s demand for a particular medical procedure is Q = 100 − PP. Draw her demand curve in PL–Q space under the assumption of no insurance and label it D1. You will have to think about the relationship between PL and PP to draw it correctly. b. Now assume the same consumer is fully insured. Think about how this affects the relationship between PL and PP and draw a full-insurance demand curve in PL– Q space. Label this curve D2. c. Finally, assume the consumer is part of a partial insurance plan with a copayment provision. Her insurance pays all expenses above and beyond her copayment of…
urgntly
Suppose that there are two countries, Beta and Gamma. Suppose further that everyone in country Beta is on Insurance B and everyone in country Gamma is on Insurance G. Suppose further that both governments use government-set price controls. In 2005, country Beta decided to change the reimbursement rate for pharmaceuticals, but country Gamma did not make this change. You, a researcher, want to study the effect of offering coverage for this drug had an impact on health expenditures. You have average health expenditures for State Beta and Gamma prior to 2005 and post-2005. Using your finding from the question above, you can infer that country Beta likely _____ reimbursement rates for pharmaceutical drugs. State Time Periods Pre-2005 Post-2005 State Beta $1000 $1400 State Gamma $1500 $1700 a. lower b. did not change c. raised
1. Given the following table *Table attached* (a) Calculate the average cost-effectiveness ratio for drug A, B, C, D, E (b) Calculate the ICER between drug B and drug C, and between drug E and drug D. (c) Draw a cost-effectiveness frontier, where Y-axis represents effectiveness, X-axis represents a cost.
Health Sector Reform is an on-going process designed to meet the growing and changingdemands of the clientele. Three types of health sector reforms are Imposed, Big ‘R’ and Small‘R’ reforms. i) Discuss the imposed health sector reform. ii) What is the nature and reason for health sector reform and iii)identify and discuss three lessons learnt from imposed health sector reform.
BN7.1 Explain the First Welfare Theorem & why it does not apply to Health Care Markets?
Demand for medical services is price inelastic (Absolute value of price elasticity of demand is less than 1 and greater than zero). Medical services are different from most other goods and services in that the person who determines the demand (the patient) is not the person who makes the payment (payment is made by the insurance company). How does this affect the price elasticity of demand for medical services (increase it or decrease it)? You may assume that this question only refers to people who have health insurance. Ignore co-payments and deductibles and any other out-of-pocket expenses. Please give an explanation.
3.
Should the FDA consider economic factors in new drug approvals?